Wedbush Reiterates Neutral Rating on Gossamer Bio, Inc. (GOSS)

Market Context

Gossamer Bio, Inc. operates in the Healthcare sector. The stock currently trades at $10.96 with a market capitalization of $824.3M. The stock has gained 378.0% over the past 52 weeks.

Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Gossamer Bio, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Gossamer Bio, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 11, 2026	Piper Sandler	Overweight	N/A
Nov 11, 2026	Wedbush	Neutral	N/A
Oct 26, 2026	Chardan Capital	Buy	N/A
Oct 15, 2026	Chardan Capital	Buy	N/A
Oct 13, 2026	Chardan Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View GOSS Stock Page